Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers
- PMID: 26101701
- PMCID: PMC4473314
Targeted inhibition of histone deacetylases and hedgehog signaling suppress tumor growth and homologous recombination in aerodigestive cancers
Abstract
Standard combined modality therapies for aerodigestive tract malignancies have suboptimal outcomes, and targeting cancer-specific molecular pathways in combination with radiation could improve the therapeutic ratio. Dysregulation of epigenetic modulators such as histone deacetylases (HDACs), and developmental morphogens such as the hedgehog (HH) pathway have been implicated in aerodigestive tumor progression and metastasis. We hypothesized that simultaneous targeting of HDACs and the HH-pathway mediator Smoothened (Smo) represents an opportunity to overcome therapeutic resistance in these cancers. We evaluated the effects of the HDAC inhibitor SAHA and Smo inhibitor GDC-0449 with radiation in multiple aerodigestive cancer cell lines. Isobologram analyses showed that SAHA and GDC-0449 synergistically suppressed cancer cell proliferation in vitro. SAHA and GDC-0449 cooperatively enhanced G0/G1 cell cycle arrest which was associated with up-regulation of p21(waf). GDC-0449 prevented SAHA-induced up-regulation of Gli-1 and Gli-2. Both Smo and Ptc-1 expression was cooperatively suppressed by SAHA and GDC-0449. The combination of SAHA and GDC-0449 induced radiation sensitization with 2 Gy as determined by colony formation assays and cytogenetic analyses, which correlated with higher residual γ-H2AX and 53BP1 foci. In mouse tumor xenografts of the SqCC/Y1 cell line, SAHA and GDC-0449 delayed tumor growth longer and prolonged survival more than either agent alone. In summary, we have identified synergistic effect of HDAC and HH signaling for radiosensitization to improve therapeutic outcomes for aerodigestive malignancies.
Keywords: Histone deacetylases; head and neck cancer; hedgehog; homologous recombination; lung cancer; lysine deacetylases; radiation sensitization; smoothened.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f1.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f2.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f3.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f4.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f5.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f6.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4473314/bin/ajcr0005-1337-f7.gif)
Similar articles
-
Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.Acta Pharmacol Sin. 2019 Feb;40(2):257-267. doi: 10.1038/s41401-018-0019-5. Epub 2018 May 18. Acta Pharmacol Sin. 2019. PMID: 29777201 Free PMC article.
-
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y. Breast Cancer Res. 2015. PMID: 25888415 Free PMC article.
-
NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.Pharmacol Res Perspect. 2014 Jun;2(3):e00043. doi: 10.1002/prp2.43. Epub 2014 Apr 7. Pharmacol Res Perspect. 2014. PMID: 25505589 Free PMC article.
-
Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer Therapy.Cancers (Basel). 2019 Apr 15;11(4):538. doi: 10.3390/cancers11040538. Cancers (Basel). 2019. PMID: 30991683 Free PMC article. Review.
-
Targeting the Sonic Hedgehog Signaling Pathway: Review of Smoothened and GLI Inhibitors.Cancers (Basel). 2016 Feb 15;8(2):22. doi: 10.3390/cancers8020022. Cancers (Basel). 2016. PMID: 26891329 Free PMC article. Review.
Cited by
-
Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia.J Transl Med. 2021 Mar 21;19(1):117. doi: 10.1186/s12967-021-02789-3. J Transl Med. 2021. PMID: 33743723 Free PMC article.
-
Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells.Cells. 2020 Dec 31;10(1):53. doi: 10.3390/cells10010053. Cells. 2020. PMID: 33396427 Free PMC article.
-
Non-canonical Hedgehog Signaling Pathway in Cancer: Activation of GLI Transcription Factors Beyond Smoothened.Front Genet. 2019 Jun 12;10:556. doi: 10.3389/fgene.2019.00556. eCollection 2019. Front Genet. 2019. PMID: 31244888 Free PMC article. Review.
-
Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.Cells. 2018 Dec 14;7(12):272. doi: 10.3390/cells7120272. Cells. 2018. PMID: 30558232 Free PMC article. Review.
-
Cell culture models of oral mucosal barriers: A review with a focus on applications, culture conditions and barrier properties.Tissue Barriers. 2018;6(3):1479568. doi: 10.1080/21688370.2018.1479568. Epub 2018 Sep 25. Tissue Barriers. 2018. PMID: 30252599 Free PMC article. Review.
References
-
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29. - PubMed
-
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784. - PubMed
-
- Robert C, Rassool FV. HDAC inhibitors: roles of DNA damage and repair. Adv Cancer Res. 2012;116:87–129. - PubMed
-
- Munshi A, Tanaka T, Hobbs ML, Tucker SL, Richon VM, Meyn RE. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol Cancer Ther. 2006;5:1967–1974. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous